Milestone Pharmaceuticals Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph G. Oliveto
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1111 Dr. Frederik-Philips Boulevard Montreal QC Canada H4M 2X6
- IPO Date
- May 9, 2019
- CIK
- 0001408443
- Website
- milestonepharma.com
- Similar Companies
- Business
- Milestone Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to the advancement and commercialization of innovative cardiac treatments. The company’s primary investigational compound, etripamil, is a unique, powerful, and fast-acting calcium channel blocker administered as a nasal spray. Etripamil has concluded its Phase III clinical program for treating paroxysmal supraventricular tachycardia (PSVT) in adults within the United States and Canada. Following the submission of its response to a Complete Response Letter, the U.S. Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025, for etripamil (CARDAMYST™) for PSVT. Additionally, etripamil is undergoing a Phase II clinical study for managing atrial fibrillation with rapid ventricular rate, with a Phase III trial anticipated to commence in 2025. Milestone Pharmaceuticals also maintains a license and collaboration agreement with Corxel Pharmaceuticals for the development and commercialization of etripamil. The company was established in 2003 and its headquarters are located in Montréal, Canada.
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Why Milestone Pharmaceuticals Stock Wilted on Wednesday
Milestone Pharmaceuticals Q1 Earnings Call Highlights
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Analysts
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Why Milestone Pharma Stock Is Taking A Dive Today
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Milestone Pharmaceuticals (NASDAQ:MIST) versus Rani Therapeutics (NASDAQ:RANI) Head to Head Review
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session